Post-Conference Perspectives

MCL and CLL: NCCN Guidelines and Treatment Options
January 21, 2020 – 
Expert insight on National Comprehensive Cancer Network guidelines with deference to chronic lymphocytic leukemia and mantle cell lymphoma.
An Overview of B-Cell Malignancies
January 21, 2020 – 
A comprehensive review of the individual diseases that constitute B-cell malignancies.
MRD Testing
January 20, 2020 – 
Ajai Chari, MD, discusses MRD testing for patients with multiple myeloma.
Quadruplet Therapy
January 20, 2020 – 
Ajai Chari, MD, discusses quadruplet therapy in patients with multiple myeloma.
Treatment for Multiple Myeloma
January 17, 2020 – 
Ajai Chari, MD, discusses treatment for patients with multiple myeloma.
Proteasome Inhibitors
January 17, 2020 – 
Ajai Chari, MD, discusses proteasome inhibitors for patients with multiple myeloma.
Current Standards of Transplant Eligibility for Patients With Multiple Myeloma
December 19, 2019 – 
Ajai Chari, MD, discusses transplant eligibility for patients with multiple myeloma.
Reimbursement With Treatment for Multiple Myeloma
January 03, 2019 – 
Rafael Fonseca, MD, discusses the reimbursement status of the various treatment options for multiple myeloma.
Studies Presented at ASH 2018 and the Outlook for Myeloma
January 03, 2019 – 
Rafael Fonseca, MD, reviews the studies presented at ASH 2018—ARROW, OPTIMISMM, and ELOQUENT-3—and shares the outlook of therapy and unmet needs in myeloma.
MRD Testing and Relapsed/Refractory Multiple Myeloma Treatment Options
December 26, 2018 – 
Rafael Fonseca, MD, defines the clinical significance of minimal residual disease (MRD) testing and the approach to relapsed/refractory for myeloma.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.